Meirluc, I believe the effort to approve DCVax-L for use in the UK is a totally different effort than the one to approve the EDEN Unit to produce it. The UK approved the commercial manufacturing capability at Sawston ages ago, doing it manually, it's doubtful if they'll even need to inspect that facility. I would think that those evaluating the EDEN are largely different people from those approving the vaccine.
In terms of numbers, regardless of precisely how many new patients are added annually in the UK, I believe there could be a substantial backlog of patients who're still considered viable who've properly stored they surgically removed tumors in the possibility of getting the vaccine on it's approval. Many who couldn't afford the compassionate use program could be in this mix, and perhaps some patients outside the UK, if their insurance permitted such action once it's approved there.
I've got to suspect that if you're a patient with Dr. Ashkan, or anyone associated with him, if you don't have the money to go for compassionate use you certainly preserve your tumor properly. My experience with most Doctors is that they're not looking out for new therapeutics, unless the patient is looking out for themselves, or have one of the rarer Drs. who's aware of the vaccine they may know nothing about it, but I still believe that there is a substantial number who do know about it, and they've prepared for it. The question may be, how do you prioritize the manufacture of the vaccine.
Gary
AI
Market Data 
Markets 
